| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
|
Designated Extension States: |
|
BA ME |
| (30) |
Priority: |
23.09.2014 US 201462054257 P
07.11.2014 US 201462076823 P
20.03.2015 US 201562136324 P
|
| (43) |
Date of publication of application: |
|
03.01.2018 Bulletin 2018/01 |
| (60) |
Divisional application: |
|
20150195.4 / 3689910 |
| (73) |
Proprietor: F. Hoffmann-La Roche AG |
|
4070 Basel (CH) |
|
| (72) |
Inventors: |
|
- POLSON, Andrew
South San Francisco, California 94080 (US)
- YU, Shang-Fan
South San Francisco, California 94080 (US)
- CHU, Yu-Waye
South San Francisco, California 94080 (US)
- WENGER, Michael
CH-4070 Basel (CH)
- HIRATA, Jamie Harue
South San Francisco, CA 94080
, (US)
- LU, Dan
South San Francisco, CA 94080 (US)
|
| (74) |
Representative: Mewburn Ellis LLP |
|
Aurora Building
Counterslip
Bristol BS1 6BX
Bristol BS1 6BX (GB) |
| (56) |
References cited: :
|
| |
|
|
- FRANCK MORSCHHAUSER ET AL: "Preliminary results of a phase II randomized study (ROMULUS)
of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in
patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL).", JOURNAL
OF CLINICAL ONCOLOGY, vol. 32, no. 15-suppl, 20 May 2014 (2014-05-20), page 8519,
XP055235812,
- MATHIAS J RUMMEL ET AL: "Bendamustine plus rituximab versus CHOP plus rituximab as
first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label,
multicentre, randomised, phase 3 non-inferiority trial", THE LANCET, vol. 381, no.
9873, 6 April 2013 (2013-04-06), pages 1203-1210, XP055235726, GB ISSN: 0140-6736,
DOI: 10.1016/S0140-6736(12)61763-2
- MEHTA AMITKUMAR ET AL: "Development and Integration of Antibody-Drug Conjugate in
Non-Hodgkin Lymphoma", CURRENT ONCOLOGY REPORTS, CURRENT SCIENCE, GB, vol. 17, no.
9, 21 July 2015 (2015-07-21), pages 1-10, XP035527919, ISSN: 1523-3790, DOI: 10.1007/S11912-015-0466-9
[retrieved on 2015-07-21]
|
|
